Ocugen Inc (OCGN)
$1.64
0.02 (1.20%)
OCGN Stock Quote Delayed 30 Minutes
OCGN Stock: 3 Big Reasons Ocugen Is Rocketing Higher Today
Investors in OCGN stock have a number of catalysts to point to today as reasons to hold onto this outperforming stock.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
422.02M
PE Ratio
-6.83
EPS
-0.24
Volume (Avg. Vol.)
3.12M
Day's Range
$1.60 - $1.69
52-Week Range
$0.35 - $2.11
Dividend & Yield
N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
Anticipation of Better Vaccine News Could Drive Ocugen Higher
From a December low of 29 cents, OCGN stock now trades at about $11, a return of over 3600%. Not bad for a name that was nearly delisted.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
What will the stock market do today? It looks like investors will continue to focus on mortgage originators and reopening plays. Here's why.
With Vaccine Distribution Profits Possible, Keep an Eye on Ocugen Stock
Ocugen has partnered on development of a credible Covid-19 vaccine. This could work wonders for OCGN stock, but it's a race to get to market in time.
OCGN Stock: Why Covid-19 Vaccine Play Ocugen Is Shooting Higher Today
OCGN stock is on the move today after vaccine partner Bharat Biotech shared positive interim results from its Phase 3 trials.
Ocugen Stock Is Preparing to Move Far Past Its All-Time High
For biotech sector investors, a regulatory green light can boost their spirits - and there's good news on that front for OCGN stock holders.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
What will the stock market do today? Investors will focus on Warren's wealth tax, EV stocks and Covid-19 hopes. Here's what to know.
The Excitement Around Ocugen Is Irrational
OCGN stock surged on news of a coronavirus vaccine, but its fundamentals do not support its stock price, making it another speculative bet.
OCGN Stock: What to Know About Red-Hot Ocugen and the India Vaccination News
OCGN stock is pulling back after a Friday rally. Here's one big piece of news that could restore faith in Ocugen shares.
Ocugen Stock Isn’t Pricing In the Hard Road Ahead
OCGN stock has soared thanks to a Covid-19 vaccine partnership. But Ocugen needs time, capital, and competitive success that may not arrive.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
What did the stock market do today? We saw growing interest in NFTs and a real potential for GME stock to hit the moon.
OCGN Stock: 2 Big Reasons Ocugen Shares Are Soaring Today
OCGN stock is on the move today thanks to two big headlines about its Covid-19 vaccine plans. Here's what to know.
OCGN Stock: Why Red-Hot Ocugen Is on the Move Today
OCGN stock is on the move today after receiving orphan drug status for its OCU400 from the European Commission. Here's what to know.
Why You Should Keep Your Distance from Ocugen Stock
Off and on the price chart OCGN stock, today's reality is bleak for shareholders, but being a bear poses its own challenges.
Ocugen Could Still Be Undervalued If Its Covid-19 Vaccine Gets OK
Ocugen could still be undervalued if the FDA approves its Covid-19 vaccine. OCGN could be worth as much as $12.73 per share, 24% higher, using scenario and probability analysis.
Why Investors Should Pay Attention to Soaring Ocugen
OCGN stock has been on a tear in recent months on speculation its therapeutics aimed at curing blindness could dominate its potential market.
Beware: Ocugen Is a Near $2 Billion Company That Has No Revenue
While the market obviously loves Ocugen’s pivot to addressing the Covid-19 pandemic, the reality is that OCGN stock doesn’t come anywhere close to deserving its newfound premium.
Entry Into Infectious Disease Field Creates Opportunity for Ocugen
Now that Ocugen is collaborating to develop a Covid-19 vaccine, OCGN stock holders should brace for a possible regulatory authorization.
Don’t Get FOMO; It’s Too Late to Jump Into Ocugen Stock
Risk-hungry traders have profited greatly from the parabolic moves of OCGN stock, but if you don't own it yet, the ship's likely sailed.
Volatile Ocugen Stock Is an Incredibly Risky Covid-19 Vaccine Play
The bear case for OCGN stock is more compelling, given the scant details surrounding the Indian Covid-19 vaccine it seeks to commercialize.
